Skip to main content
Log in

Successful Treatment of Idiopathic Hypereosinophilic Syndrome with Imatinib Mesylate: A Case Report

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Patients with idiopathic hypereosinophilic syndrome (HES) show persistent hypereosinophilia of unknown etiology that is associated with end-organ damage. Different treatments, including the use of corticosteroids and cytotoxics, have been investigated for HES with modest success. We describe a patient with HES who had significant end-organ damage from hypereosinophilia and remained refractory to conventional therapy. Therapy with imatinib mesylate, a selective tyrosine kinase inhibitor that is highly effective in treating patients with BCR-ABL-positive chronic myeloid leukemia, was tried with the patient. The result was impressive, with hematologic remission achieved after 12 days of administration. Our finding concurs with recent reports that imatinib mesylate may be a promising agent in the treatment of some cases of HES.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759–2779.

    PubMed  CAS  Google Scholar 

  2. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1–27.

    Article  PubMed  CAS  Google Scholar 

  3. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577–1578.

    Article  PubMed  CAS  Google Scholar 

  4. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003; 101:4714–4716.

    Article  PubMed  CAS  Google Scholar 

  5. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–1214.

    Article  PubMed  CAS  Google Scholar 

  6. Apperley JF, Gardembas, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481–487.

    Article  PubMed  CAS  Google Scholar 

  7. Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol. 1996;95:2–9.

    PubMed  CAS  Google Scholar 

  8. Flaum MA, Schooley RT, Fauci AS, Gralnick HR. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome, I: hematologic manifestations. Blood. 1981;58:1012–1020.

    PubMed  CAS  Google Scholar 

  9. Parrilo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978;89:167–179.

    Article  Google Scholar 

  10. Parillo JE, Lawley TJ, Frank MM, Kaplan AP, Fauci AS. Immunologic reactivity in the hypereosinophilic syndrome. J Allergy Clin Immunol. 1979;64:113–121.

    Article  Google Scholar 

  11. Izumi T, Kishimoto S, Takano T, et al. Expression of human platelet-activating factor receptor gene in EoL-1 cells following butyrate-induced differentiation. Biochem J. 1995;305:829–835.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Seguchi M, Nakajima S. Induction of ICAM-1 expression on the eosinophilic leukemia cell line-3 (EoL-3) by platelet-activating factor and platelet factor 4. Ann Allergy Asthma Immunol. 1995;74:255–257.

    PubMed  CAS  Google Scholar 

  13. Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med. 1983;52:1–22.

    PubMed  CAS  Google Scholar 

  14. Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer. 1991;67:2826–2827.

    Article  PubMed  CAS  Google Scholar 

  15. Murphy PT, Fennelly DF, Stuart M, O'Donnell JR. Alfa-interferon in a case of hypereosinophilic syndrome. Br J Haematol. 1990;75:619–620.

    Article  PubMed  CAS  Google Scholar 

  16. Zilinsky RM, Lawrence WD. Interferon-a for the hypereosinophilic syndrome. Ann Intern Med. 1990;113:716–718.

    Article  Google Scholar 

  17. Archimbaud E, Guyotat D, Guillaume C, Godard J, Fiere D. Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation. Am J Hematol. 1988;27:302–303.

    Article  PubMed  CAS  Google Scholar 

  18. Esteva-Lorenzo FJ, Meechan KR, Spitzer TR, Mazumder A. Allogeneic bone marrow transplant in a patient with hypereosinophilic syndrome. Am J Hematol. 1996;51:164–165.

    Article  PubMed  CAS  Google Scholar 

  19. Sigmund DA, Flessa HC. Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:647–648.

    PubMed  CAS  Google Scholar 

  20. Fukushima T, Kuriyama K, Ito H, et al. Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome. Br J Haematol. 1995;90:213–215.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D. Tan.

About this article

Cite this article

Tan, D., Hwang, W., Ng, H.J. et al. Successful Treatment of Idiopathic Hypereosinophilic Syndrome with Imatinib Mesylate: A Case Report. Int J Hematol 80, 75–77 (2004). https://doi.org/10.1532/IJH97.A20309

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1532/IJH97.A20309

Key words

Navigation